[Management of pulmonary circulation alterations].
Quero Jiménez
M C
MC
Servicio de Cardiología Pediátrica, Hospital Ramón y Cajal, Madrid.
Burgueros Valero
M
M
González Dieguez
C
C
Domínguez Pérez
F
F
Pinto Corraliza
J
J
Rodríguez Fernández
M
M
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007231:Infant, Newborn; D007511:Ischemia / Q000503:physiopathology; D007650:Ketanserin / Q000627:therapeutic use; D008168:Lung / Q000098:blood supply; D009569:Nitric Oxide / Q000627:therapeutic use; D010100:Oxygen / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011453:Prostaglandins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D011458:Prostaglandins E / Q000627:therapeutic use; D011652:Pulmonary Circulation / Q000502:physiology*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins; D011458:Prostaglandins E; D014665:Vasodilator Agents; D009569:Nitric Oxide; D007650:Ketanserin; D010100:Oxygen
Manejo de las alteraciones de la circulación pulmonar.